Health insurance; coverage for cancer follow-up testing, report.
HB2611 would require health insurers, health maintenance organizations, and related health coverage issuers in Virginia to cover cancer follow-up testing when it is recommended by a licensed health care provider after cancer treatment. The bill defines cancer follow-up testing broadly to include diagnostic testing, screening, imaging, and other medically necessary procedures used to monitor for recurrence or progression. Covered services specifically include MRI, CT, PET scans, ultrasounds, blood tests, biopsies, tumor marker screenings, and any other follow-up tests deemed necessary by the provider.
The bill also limits cost-sharing for this care. While insurers may still apply deductibles, coinsurance, or other general cost-sharing rules under a policy, they may not impose special cost-sharing specifically on cancer follow-up testing received from participating providers. The mandate would apply to most individual and group accident and sickness policies, subscription contracts, and health maintenance organization plans, but it excludes short-term travel, accident-only, limited or specific disease policies other than cancer policies, short-term nonrenewable policies of six months or less, and Medicare-related or similar governmental coverage. The bill would take effect for policies issued, renewed, or extended on or after January 1, 2026, and it requires the State Corporation Commission’s Bureau of Insurance to report annually on utilization, premium impacts, and any recommended policy changes.
HB2611 would add a new section to Virginia insurance law, creating an explicit coverage mandate for cancer follow-up testing in the individual and group health insurance market. It would affect insurers, subscription contract providers, and HMOs by requiring coverage for post-treatment monitoring services and by limiting any special copayments or other cost-sharing targeted at those services for participating providers. The bill also directs the Bureau of Insurance to collect and report data on the number of people helped and the effect on premiums, creating an ongoing oversight mechanism tied to the new mandate.
The available voting history suggests the bill had at least some support in subcommittee, with a 7-0 recommendation to lay it on the table, which indicates no recorded opposition in that vote. Because there are no committee transcripts provided, there is little direct evidence of debate, but the bill’s structure suggests it was framed as a patient-protection measure aimed at improving access to medically necessary cancer surveillance. Overall, the limited record points to a generally favorable or noncontroversial reception at the subcommittee stage, at least procedurally.
The main policy tension in HB2611 is between expanding access to cancer surveillance and limiting added costs for insurers and premiums. Supporters would likely emphasize that follow-up testing is medically necessary to detect recurrence early and that patients should not face special copays for recommended monitoring. Potential concerns, though not documented in transcripts, would likely center on premium impacts, administrative complexity, and the scope of the mandate, especially the broad definition of covered follow-up testing and the requirement to cover provider-recommended services. The bill addresses some of those concerns by excluding certain limited policies and by requiring annual reporting on premium effects.